Downregulation of GFPT2 enhances cisplatin chemotherapy sensitivity in STK11/KRAS mutant non-small cell lung cancer by regulating the hexosamine biosynthesis pathway, resisting tumor growth
Our study found that inhibiting GFPT2 can enhance the chemotherapy sensitivity of cisplatin to STK11/KRAS/LKB1 mutant NSCLCs cells through the OGT mediated HBP pathway, filling a key gap in the chemotherapy resistance mechanism of KRAS/LKB1 mutant lung cancer.
Authors
- Jun Jiang (ORCID: https://orcid.org/0009-0000-3404-2071)
- Peng Wang (ORCID: https://orcid.org/0000-0002-8234-9059)
- Cheng Zhang (ORCID: https://orcid.org/0000-0002-1290-8855)
- Yirong Wang (ORCID: https://orcid.org/0000-0002-1995-2728)
- Xiaonan Yin (ORCID: https://orcid.org/0000-0002-4688-9496)
Institutions
- Shandong University of Aeronautics (CN)
- Yantai University (CN)
- Shandong Institute of Food and Drug Inspection (CN)
- Yantai Academy of Agricultural Sciences (CN)
- Yantaishan Hospital (CN)
Publication Details
- Journal
- Cytokine
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.cyto.2025.156943
- Citations
- 3
- Primary Topic
- Glycosylation and Glycoproteins Research
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Wuhan Science and Technology Project